Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.

NCT06169579 is registered in ClinicalTrials.gov with Shenzhen NewDEL Biotech, Co., Ltd as lead sponsor.

NCT NCT06169579
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06169579 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm, Non-randomized, Open-label, Dose-escalation and Dose-expansion, Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles, as Well as Preliminary Efficacy, of ND-003 in Chinese Patients With Advanced Solid Tumors.
Lead sponsor
Shenzhen NewDEL Biotech, Co., Ltd
Phase
Phase 1
Overall status
Enrolling by invitation
Start date
February 4, 2024
Completion date
December 31, 2028
Enrollment
96 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor